UPDATE: Jefferies & Company Initiates Coverage on Antares Pharma with Buy Rating, $5 PT

In a report published Wednesday, Jefferies & Company initiated coverage on Antares Pharma ATRS with a Buy rating and $5.00 price target. Jefferies noted, “We are initiating on ATRS with a Buy and a 12-month $5 price target. ATRS is a needle auto-injector innovator transitioning from a device technology partner to an integrated commercial-stage drug company. The primary driver is a self-injected once-weekly form of methotrexate for RA (NDA filed 12/17/12) with better safety and efficacy potential. In the meantime, several already-partnered drugs should fund pre-launch preparations in '13.” Antares Pharma closed on Tuesday at $3.82.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorInitiationAnalyst RatingsJefferies & Company
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!